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A significant effort was done to formulate transdermal patches (Paranjothi 1998) of 
Diltiazem Hydrochloride (DH), a benzothiazepine calcium channel blocker, mainly meant 
for the treatment of hypertension, chronic stable angina pectoris; by using hydroxy ethyl 
cellulose, ethyl cellulose and Eudragit RLPO. Six batches of transdermal patches were 
prepared by solvent casting technique in which the best formulation was found out. The 
polymers HEC, EC and Eudragit RLPO were incorporated with Diltiazem Hydrochloride in 
various proportions, out of which the best formulation on the ratio [HEC: EC: EUDRAGIT 
RLPO-1:1:2] with the drug was determined. The prepared transdermal patches were 
spherical, uniform in shape and white in color. The obtained transdermal films were 
evaluated for physico-chemical characteristics, in vitro release profile and in vivo evaluation 
in albino mice. Higuchis plot studies revealed that the predominant mechanism of drug 
release was diffusion. 
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Most highly remarkable efforts have 
been highly focused on the development of 
new drug delivery system. The new drug 
delivery system can improve patient’s 
convenience and compliance due to less 
frequent administration. Moreover, the 
maximum utilization of drug enabling 
reduction in the total amount of dose 
administered, the design of any controlled 
transdermal drug release delivery system is 
subjected to several variables of considerable 
importance among them are the route of drug 
delivery system, the diseases being treated 
,the patients, the length of the therapy, and 
the properties  of the drug. The transdermal 
drug delivery is required not only for the 
local targeting of the drugs but also for a 
better control systemic drug delivery 
(Panchagunta 1997). The Diltiazem 
Hydrochloride (DH), a benzothiazepine 
calcium channel blocker is used alone or with 
an angiotensin converting enzyme inhibitor 
to treat hypertension, a chronic stable angina 
pectoris, and prinzmetal’s  variant angina. 
The drug is having the bioavailability about 
15-30%, protein binding capacity as 70-
80%.Diltiazem is metabolized in the liver and 
excreted in the urine. The elimination t1/2 are 
in the range of2-6h.The total oral dose is 30-
60mg\thrice in a day and going for 
parentrals; it is 25mg\5mL injection. The 
molecular weight of the drug is 414.519g 
\mol. Melting point is around2310c, its 
having log\hydrophobicity of about 3.141, 
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were the various important criteria which 
should be considered [DH] for transdermal 
drug delivery. 
 
Materials and Methods 
Solvent casting technique 
Accurately weighed quantity of HEC, 
EC and Eudragit RLPO compositions of 
different formulations [6 Batches] got mixed 
with 10.2mg of Diltiazem Hydrochloride. Out 
of various formulations; the best batch was 
found out. The transdermal films of DH were 
prepared by weighing accurately 10.2mg of 
DH incorporated with [HEC: EC: EUDRAGIT 
RLPO -1:1:2] ratio, and then it was  
transferred to a beaker containing 2.9 mL of 
distilled water. The solutions were mixed to 
get a clear solution. Glycerin was added as 
plasticizer. The whole solution were poured 
over mercury surface in a petridish and 
allowed to dry at room temperature. The 
same procedure was repeated with 
compositions of different formulation of drug 
with polymers. 
 
 In vitro drug release evaluation 
Commercial semi-permeable 
membrane was employed in this study. The 
membrane used was transparent and 
regenerated cellulose type, which was 
permeable to low molecular weight 
substances (Naik 1993). A film of size 1cm 
diameter was cut and placed on the semi 
permeable membrane. The semi-permeable 
membrane was tied to one end of an open 
ended cylinder which acted as donor 
compartment. The entire surface of the 
membrane was in contact with the receptor 
compartment containing 300mL of phosphate 
buffer [PH7.4]. The content of the 
compartment was agitated by a magnetic 
stirrer. Samples of 1mL were withdrawn from 
receptor compartment and replaced by equal 
volumes of fresh media. The withdrawn 
samples were analysed using UV- visible 
spectrophotometer at 269 nm using reagent 
blank (Table 1). 
Table 1: In vitro drug release data 
[HEC: EC: EUDRAGIT RLPO -1:1:2] 
Time in 
Minutes 
Drug 
release in 
mg 
Cumulative % 
Drug Release 
30 0.896 8.96 
60 2.610 26.10 
90 4.416 44.16 
120 6.180 61.80 
150 8.760 87.60 
180 9.216 92.16 
 
Table 2: In vivo drug release data 
[HEC: EC: EUDRAGIT RLPO -1:1:2] 
Time 
in 
hours 
Percentage of 
drug 
remaining 
[mg] 
Amount 
of drug 
release 
[mg] 
Percentage 
drug 
release 
1 9.29 0.91 9.10 
2 7.73 2.47 24.70 
3 6.31 3.89 38.90 
4 5.42 4.78 47.80 
5 3.74 6.46 64.60 
6 2.55 7.65 76-50 
In vivo studies 
A healthy albino mouse weighing 1.5-
2.5 kg was taken, which was already checked 
for absence of any diseases. The dorsal 
surface of the albino mice was shaved and the 
transdermal patches having the size of 1cm 
containing 10.2 mg of DH was placed over 
the shaved surface. Dextrose solution was 
transfused continuously throughout the 
period of study. Periodically 1mL blood 
samples were taken using a syringe, which 
already contained 1 mL of 3.8% of sodium 
citrate solution to prevent blood clotting 
(Basak 1997). These blood samples were 
subjected for centrifuging at 2200rpm for 
about 20 minutes.1mL of the supernatant 
liquid was taken from this and after suitable 
dilution these samples were analysed at 
269nm using UV- visible spectrophotometer. 
The in vivo studies conducted for the 
transdermal patches of DH in albino mice 
showed zero order release pattern.  The in 
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vivo study of the transdermal patches didn’t 
show any inflammation or any other 
sensitization reaction at the administration 
site (Table 2). 
Table 3: Composition of formulations 
Batch 
Code 
Polymers Solvent Plasticizer 
HEC 
(%) 
EC 
(%) 
EUDRAGIT 
RLPO (%) 
Water 
(mL) 
Glycerine 
(% W/W) 
B1 1 1 1 2.5 30 
B2 2 1 1 2.5 30 
B3 1 2 1 2.5 30 
B4 1 1 2 2.5 30 
B5 2 2 1 2.5 30 
B6 2 1 2 2.5 30 
Concentration of Plasticizer = 30%W/W; Amount of drug loaded in each film = 10mg; 
1% W/V = 50 mg; 2% W/V = 100 mg 
Results and Discussion 
The transdermal patches were 
subjected to various physico-chemical 
evaluation tests such as percentage moisture 
absorption, percentage moisture loss, 
swelling index, time taken for maximum 
swelling, water vapour transmission rate, 
folding endurance, drug content uniformity 
etc. The films were also subjected to in vitro 
dissolution studies, and in vivo studies using 
albino mice. The physico-chemical 
evaluations of the formulations have shown 
different physical characteristics of the 
formulations changed according to the nature 
and composition of the polymers (Table 3).  
In vitro dissolution study of drug along with 
different concentrations of polymers i.e; HEC, 
EC and Eudragit RLPO have been performed 
(Rove 2003). The higher rate and percentage 
of release of drugs in the film containing high 
concentration of Eudragit RLPO [HEC: EC: 
Eudragit RLPO-1:1:2] is considered as the 
best batch. As the percentage of Eudragit 
RLPO was enhanced, the rate of the release of 
drug was increased. Hence the batch [HEC: 
EC: EudragitRLPO-1:1:2] shows the best 
nature of films and the graph representing 
the best controlled drug release. In addition, 
it shows better stability and suitability. 
 
Conclusion 
The transdermal films prepared by 
solvent casting technique were spherical, 
uniform in shape and white color in nature 
(Mandal 1991). The formulation containing 
two parts of Eudragit RLPO, one part of HEC 
and EC respectively has shown best release in 
the concentration independent manner. Good 
correlation has been observed between the in 
vitro and in vivo profile and hence revealed 
the ability of the formulation to reproduce the 
in vitro release pattern through the biological 
membrane. 
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